Oncotelic Therapeutics, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 26, 2026, disclosing a presentation made by Chief Business Officer Saran Saund at the 22nd Drug Discovery Strategic Summit.
The event took place on October 21–22, 2026, at the Westin San Francisco Airport in Millbrae, California. During the summit, Saund presented a paper titled "Partitioning 29 Million PubMed Abstracts by Disease Turns a Literature Review into a Discovery. A Four-Gene mTOR Signature Defining a Candidate Hepatocellular Carcinoma Population."
The presentation detailed the Company’s Partitioned Literature Aggregation (PLA) framework. According to the filing, the framework combines literature analysis with gene-expression and survival analyses to identify a four-gene mTOR-related signature associated with patient outcomes in liver cancer.
The filing also noted that Oncotelic plans to expand the PLA framework through autonomous AI agents. The Company outlined a research environment targeting 100 billion protein-related vectors to support drug discovery across multiple disease areas.
The presentation is included as Exhibit 99.1 to this Form 8-K filing.
